Vimarsana
Biggest News Aggregation in the World

James Freddo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from James Freddo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In James Freddo Today - Breaking & Trending Today

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at ... - Vimarsana News

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at ...

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel

TRACON Pharmaceuticals Inc achieves positive results based on Double-Digit Objective Response Rate in each cohort from ENVASARC Phase 2 Pivotal Trial - Vimarsana News

TRACON Pharmaceuticals Inc achieves positive results based on Double-Digit Objective Response Rate in each cohort from ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Inc (NASDAQ:TCON) revealed that its PD-L1 antibody envafolimab achieved positive results based on the double-digit Objective Response...

TRACON Pharmaceuticals Inc says ENVASARC trial gets recommendation to proceed as planned - Vimarsana News

TRACON Pharmaceuticals Inc says ENVASARC trial gets recommendation to proceed as planned

TRACON Pharmaceuticals (NASDAQ:TCON) Inc has announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that...

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial - Vimarsana News

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

10.08.2022 - Trial to Continue as PlannedSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) - TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its ... Seite 1